Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) Assets Average (2021 - 2025)

Lyra Therapeutics has reported Assets Average over the past 5 years, most recently at $39.9 million for Q4 2025.

  • Quarterly results put Assets Average at $39.9 million for Q4 2025, down 44.99% from a year ago — trailing twelve months through Dec 2025 was $39.9 million (down 44.99% YoY), and the annual figure for FY2025 was $51.2 million, down 50.97%.
  • Assets Average for Q4 2025 was $39.9 million at Lyra Therapeutics, down from $48.1 million in the prior quarter.
  • Over the last five years, Assets Average for LYRA hit a ceiling of $142.1 million in Q1 2024 and a floor of $39.9 million in Q4 2025.
  • Median Assets Average over the past 5 years was $86.7 million (2024), compared with a mean of $88.3 million.
  • Biggest five-year swings in Assets Average: soared 99.42% in 2023 and later plummeted 56.83% in 2025.
  • Lyra Therapeutics' Assets Average stood at $61.3 million in 2021, then surged by 87.09% to $114.7 million in 2022, then increased by 14.71% to $131.6 million in 2023, then plummeted by 44.86% to $72.6 million in 2024, then plummeted by 44.99% to $39.9 million in 2025.
  • The last three reported values for Assets Average were $39.9 million (Q4 2025), $48.1 million (Q3 2025), and $54.4 million (Q2 2025) per Business Quant data.